Current role
Matthew B. Frankel
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Matthew B. Frankel
Chemomab Therapeutics Ltd. reported in an 8-K filed November 14, 2022 that Matthew B. Frankel was appointed Chief Medical Officer & VP, Drug Development, effective November 14, 2022.
“On November 14, 2022, Chemomab Therapeutics Ltd. (the "Company") announced the appointment of Dr. Matthew B. Frankel as Chief Medical Officer & VP, Drug Development of the Company.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2022-11-14–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Chemomab Therapeutics Ltd.
Other people whose current roles at this company are on record from its filings.
- Adi Mor CEO, Board Member
- Dale Pfost CEO, Board Member
- Dr. Adi Mor CEO
- Dr. Dale Pfost CEO
- Neil Cohen CEO, Board Member
- Dr. Nissim Darvish Chairman
- Stephen Squinto Chairman, Board Member
- Andrew Fine CFO
- Donald Marvin CFO, COO
- Ms. Sigal Fattal CFO
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.